S-1/A: NeOnc Technologies Holdings Files for $75 Million IPO to Advance Brain Cancer Therapies

NeOnc Technologies Holdings is seeking to raise $75 million through an initial public offering to fund clinical trials and research into novel brain cancer treatments.

Summary

• NeOnc Technologies Holdings, a clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement for a proposed initial public offering.
• The company plans to offer 6,000,000 shares of common stock, with an anticipated initial public offering price between $11.25 and $13.75 per share, based on an assumed public offering price of $12.50 per share.
• NeOnc is focused on developing treatments for intracranial malignancies, utilizing novel drug delivery methods in combination with drug candidates.
• The company's lead products include NEO100, administered intranasally for recurrent malignant glioma and skull-based meningioma, and NEO212, an orally administered molecule for primary and secondary brain tumors.
• NeOnc intends to use approximately $23.7 million of the net proceeds for clinical trials, $11.4 million for research and development, $10.0 million to repay a short term loan, and $29.9 million for general corporate purposes.
• The company had a net loss of $14.9 million in 2023 and an accumulated deficit of $38.7 million as of December 31, 2023.
• NeOnc has applied to list its common stock on the Nasdaq Global Market under the symbol NTHI, contingent upon the closing of the offering.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights the potential of the company's products and the growing market opportunity, it also acknowledges the significant financial challenges and risks associated with drug development and regulatory approval.

Positives

• NEO100 has shown promise in Phase I trials, with some patients experiencing longer-than-expected survival rates.
• NEO212 has received IND approval, allowing it to proceed to clinical testing in cancer patients.
• The company has exclusively licensed a large worldwide patent portfolio from the University of Southern California.
• The company projects that the readout for its Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing its original timeline by a full year from 2025.
• The company is targeting a CNS treatment market estimated to grow at 9.4% CAGR to $166.5 billion by 2028.

Negatives

• The company has incurred significant losses since its inception and anticipates increasing losses for the foreseeable future.
• The company has never generated any significant revenue from product sales and does not anticipate generating significant revenues for the foreseeable future.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company will require additional financing to advance the development of its product candidates, which may not be available on acceptable terms, or at all.
• The company's product candidates are in preclinical and clinical stages of development and might never receive regulatory approval or become commercially viable.
• The company faces significant competition from other biopharmaceutical and biotechnology companies.
• The company may not be successful in its efforts to expand its pipeline of product candidates and develop marketable products.
• The company is highly dependent on its key personnel, and the loss of their services could harm the business.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval.

Management Comments

• The company believes that the targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite the trial process.
• The company projects that the readout for its Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing its original timeline by a full year from 2025.

Industry Context

The CNS treatment market is estimated to grow at 9.4% CAGR to $166.5 billion by 2028, and the global brain tumor drug market to grow at CAGR of 9.0% to $4.4 billion by 2029, according to Fortune Business Insights. The malignant Glioblastoma Multiforme (GBM) drug market is expected to grow at 12.7% CAGR to $2.3 billion by 2029, according to iHealthcareAnalys.

Comparison to Industry Standards

• The document references several clinical trials and studies by other groups that were also performed with recurrent glioblastoma patients.
• It compares the survival rates of patients treated with NEO100 in the company's Phase I trial to those in other studies using treatments like lomustine and bevacizumab.
• The document also mentions the Optune device by Novocure as a non-invasive treatment for glioblastoma.

Legal Proceedings

• The company settled a dispute with a former licensee for $0.6 million.
• The company settled a dispute with Orient EuroPharma Co., Ltd. (OEP) for $4.0 million.

Related Party Transactions

• Amir Heshmatpour, the sole member and managing director of AFH Holdings and Advisory, LLC (AFH) and a member of NeOncs Board of Directors, was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing.
• AFH shall be paid in cash an aggregate fee in an amount equal to 2% of the post-money valuation of NeOnc Technologies Holdings, Inc. immediately after the consummation of this offering.
• The company intends to use $10.0 million of the net proceeds to repay a short term loan (the HCWG Loan) provided to us by HCWG LLC, an entity substantially beneficially owned by our officers and directors.
• The company has incurred $798,743 and $0 for the years ended December 31, 2023 and 2022 for compensation to the three officers of our company, two of whom are shareholders.
• The company has exclusively licensed a large worldwide patent portfolio from the University of Southern California (USC).
• The company must pay USC $230,000 by March 31, 2024.
• The company issued 560,000 shares of common stock of NTHI on October 11, 2023 to USC.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the development of new and effective brain cancer treatments.
• The company's success will depend on its ability to attract and retain qualified personnel.

Next Steps

• Continue Phase IIa clinical trial for NEO100.
• Initiate Phase I/II trial for oral NEO212.
• Pursue preclinical development of other product candidates.
• Seek regulatory approvals for product candidates.
• Establish commercial manufacturing capabilities.
• Establish strategic licensing or other arrangements.

Key Dates

Keywords

NEO100, NEO212, glioblastoma, brain cancer, clinical trials, biopharmaceutical, IPO, perillyl alcohol, intranasal delivery, FDA